Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.22.01667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Marco Tagliamento und 52 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy. Hauptthemen laut MEDLINE: COVID-19, Breast Neoplasms, Vaccines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Cancer Research UK.
Abstract (Originalsprache)
PURPOSE Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination trials, a contemporary real-world evaluation of outcomes during the various pandemic phases, as well as of the impact of vaccination, is needed to better inform clinical practice. METHODS We compared COVID-19 morbidity and mortality among patients with breast cancer across prevaccination (February 27, 2020-November 30, 2020), Alpha-Delta (December 1, 2020-December 14, 2021), and Omicron (December 15, 2021-January 31, 2022) phases using OnCovid registry participants (ClinicalTrials.gov identifier: NCT04393974 ). Twenty-eight-day case fatality rate (CFR 28 ) and COVID-19 severity were compared in unvaccinated versus double-dosed/boosted patients (vaccinated) with inverse probability of treatment weighting models adjusted for country of origin, age, number of comorbidities, tumor stage, and receipt of systemic anticancer therapy within 1 month of COVID-19 diagnosis. RESULTS By the data lock of February 4, 2022, the registry counted 613 eligible patients with breast cancer: 60.1% (n = 312) hormone receptor–positive, 25.2% (n = 131) human epidermal growth factor receptor 2–positive, and 14.6% (n = 76) triple-negative. The majority (61%; n = 374) had localized/locally advanced disease. Median age was 62 years (interquartile range, 51-74 years). A total of 193 patients (31.5%) presented ≥ 2 comorbidities and 69% (n = 330) were never smokers. In total, 392 (63.9%), 164 (26.8%), and 57 (9.3%) were diagnosed during the prevaccination, Alpha-Delta, and Omicron phases, respectively. Analysis of CFR 28 demonstrates comparable estimates of mortality across the three pandemic phases (13.9%, 12.2%, 5.3%, respectively; P = .182). Nevertheless, a significant improvement in outcome measures of COVID-19 severity across the three pandemic time periods was observed. Importantly, when reported separately, unvaccinated patients from the Alpha-Delta and Omicron phases achieved comparable outcomes to those from the prevaccination phase. Of 566 patients eligible for the vaccination analysis, 72 (12.7%) were fully vaccinated and 494 (87.3%) were unvaccinated. We confirmed with inverse probability of treatment weighting multivariable analysis and following a clustered robust correction for participating center that vaccinated patients achieved improved CFR 28 (odds ratio [OR], 0.19; 95% CI, 0.09 to 0.40), hospitalization (OR, 0.28; 95% CI, 0.11 to 0.69), COVID-19 complications (OR, 0.16; 95% CI, 0.06 to 0.45), and reduced requirement of COVID-19–specific therapy (OR, 0.24; 95% CI, 0.09 to 0.63) and oxygen therapy (OR, 0.24; 95% CI, 0.09 to 0.67) compared with unvaccinated controls. CONCLUSION Our findings highlight a consistent reduction of COVID-19 severity in patients with breast cancer during the Omicron outbreak in Europe. We also demonstrate that even in this population, a complete severe acute respiratory syndrome coronavirus 2 vaccination course is a strong determinant of improved morbidity and mortality from COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
- Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
- Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
- Department of Gynecology and Obstetrics, Breast Center and Gynecological Cancer Center and CCC Munich, University Hospital Munich, Munich, Germany.
- Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
ORCID-Profile: Marco Tagliamento, Matteo Lambertini, Ramon Salazar, Nadia Harbeck, Lucia Del Mastro, Juan Aguilar-Company, Mark Bower, Alessia Dalla Pria, Jasmine Handford, Ailsa Sita-Lumsden, Clara Martinez-Vila, Bruno Vincenzi, Giuseppe Tonini, Joan Brunet, Paolo Pedrazzoli, Francesca D'Avanzo, Alvin J X Lee, Sabrina Rossi, Gianpiero Rizzo, Oriol Mirallas, Isabel Pimentel, Annalisa Guida, Rossana Berardi, Alessandro Parisi, Avinash Aujayeb, Aleix Prat, Salvatore Grisanti, Maura Rossi, Daniele Generali, Cristina Saura, Gary H Lyman, Nicole M Kuderer, David J Pinato, Alessio Cortellini
Förderung
- Wellcome Trust
- Cancer Research UK
Zitieren
APA
Tagliamento, M., Gennari, A., Lambertini, M., Salazar, R., Harbeck, N., Del Mastro, L., Aguilar-Company, J., Bower, M., Sharkey, R., Dalla Pria, A., Plaja, A., Jackson, A., Handford, J., Sita-Lumsden, A., Martinez-Vila, C., Matas, M., Miguel Rodriguez, A., Vincenzi, B., Tonini, G., …, & Cortellini, A. (2023). Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.01667
Vancouver
Tagliamento M, Gennari A, Lambertini M, Salazar R, Harbeck N, Del Mastro L, et al. Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.01667
BibTeX
@article{Tagliamento2023,
author = {Tagliamento, Marco and Gennari, Alessandra and Lambertini, Matteo and Salazar, Ramon and Harbeck, Nadia and Del Mastro, Lucia and Aguilar-Company, Juan and Bower, Mark and Sharkey, Rachel and Dalla Pria, Alessia and Plaja, Andrea and Jackson, Amanda and Handford, Jasmine and Sita-Lumsden, Ailsa and Martinez-Vila, Clara and Matas, Marta and Miguel Rodriguez, Ana and Vincenzi, Bruno and Tonini, Giuseppe and Bertuzzi, Alexia and Brunet, Joan and Pedrazzoli, Paolo and D'Avanzo, Francesca and Biello, Federica and Sinclair, Alasdair and Lee, Alvin J X and Rossi, Sabrina and Rizzo, Gianpiero and Mirallas, Oriol and Pimentel, Isabel and Iglesias, Maria and Sanchez de Torre, Ana and Guida, Annalisa and Berardi, Rossana and Zambelli, Alberto and Tondini, Carlo and Filetti, Marco and Mazzoni, Francesca and Mukherjee, Uma and Diamantis, Nikolaos and Parisi, Alessandro and Aujayeb, Avinash and Prat, Aleix and Libertini, Michela and Grisanti, Salvatore and Rossi, Maura and Zoratto, Federica and Generali, Daniele and Saura, Cristina and Lyman, Gary H and Kuderer, Nicole M and Pinato, David J and Cortellini, Alessio},
title = {Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.22.01667}
}
EUVIMED